NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Seems that a few weeks after you’d asked Denise Heady at UCLA (back in January 20, 2020) whether the vaccine they were using for their combo trial in recurrent GBM trial, I’d met and spoke directly with both Dr. Linda Liau and Dr. P. Leia Nghiemphu in person at a small event held in Orange County on February 12, 2020, where they both told me directly that the vaccine they were using was indeed DCVax-L, but that they couldn’t use the trade name, since Northwest was not sponsoring the trial.

So were Linda Liau and Dr. Nghiemphu lying when they told me that?
Was I lying?

Here’s a link to the event:
https://www.eventbrite.com/e/ucla-brain-tumor-center-community-lecture-tickets-86420539159

And listed below is my post that I'd made while I was present at the event stating that she'd told me this.

sentiment_stocks

Wednesday, February 12, 2020 9:16:19 PM
Re: None
Post# 264504 of 461022 Go
So I’m at the UCLA event right now, and it’s pretty small. I saw LL standing with another UCLA doctor -Dr. N -her name is a bit hard to remember without looking it up. Anyhow, since there wasn’t really anyone talking to her, I was able to introduce myself. Of course, I prefaced that I was an investor in NWBO. She told me she wasn’t part of the company, bless her heart (she’s so cute and sweet and little). Anyhow in our conversation, I was able to confirm that the vaccine in the UCLA trial being combined with Keytruda (she corrected me and called it Pembro, and then confirmed that Keytruda was the brand name of the same) is hands down DCVax-L.. but they can’t use the trademarked name since NWBO isn’t sponsoring the trial (because they don’t have the money to do so right now). But she can use the DCVax-L formula there at UCLA as it was developed at the University.

The presentation hasn’t started yet, but I imagine that will likely be the most material thing I will learn here. :)

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153800290

The next day, I’d written another post indicating that I’d spoken with Dr. Nghiemphu and that she, too, had confirmed that the ATL-DC vaccine UCLA was using in their combo trial was indeed DCVax-L.

sentiment_stocks

Thursday, February 13, 2020 1:44:08 AM
Re: jdheart101 post# 264505
Post# 264533 of 461018 Go
After the presentation, I had an opportunity to speak with Dr. N (Nghiemphu) who also told me, unsolicited (she brought it up to me - I didn’t ask) that they are using DCVax-L with Keytruda in the recurrent GBM trial. There wasn’t an opportunity during the Q and A... in fact, the Recurrent trial itself was not mentioned during the presentation. The presentation was more broad and generalised.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153802313&txt2find=Nghiemphu

and...

sentiment_stocks

Thursday, February 13, 2020 10:54:37 AM
Re: longfellow95 post# 264585
Post# 264604 of 461020 Go

Dr Prins supposedly stated in an email,

We have always had our own IND with the FDA for this vaccine and I think this is in keeping with the vaccine still being DCVax-L, it’s just that UCLA has their own IND to work with it.

But hands down, LL and Dr Nghiemphu stated the autologous DC vaccine was DCVax-L, but that they couldn’t use the trade name.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153809180&txt2find=Nghiemphu

About Dr. P. Leia Nghiemphu
https://www.uclahealth.org/providers/phioanh-nghiemphu

Adam writes that Northwest Bio doesn’t have the rights to ATL-DC. Of course, that’s a rather sloppy way of putting it, but let’s dive down on what he might have meant by that statement.

Does Adam mean NWBO doesn’t have the right to control the combo trial at UCLA?
Okay, he’d be right. It’s UCLA’s trial, not Northwest’s.

Does Adam mean NWBO doesn’t have the right to use the data to the combo trial at UCLA?
He’d be right about that, too. It’s UCLA’s data.

But if the ATL-DC vaccine for which the trademarked name is DCVax-L (which is what Adam's emails indicate to be the case) extends life for rGBM patients in combo with a checkpoint inhibitor, where would a patient go to obtain this ATL-DC vaccine for which the trademarked name is DCVax-L?

How would a doctor prescribe it?

Would they prescribe an ATL-DC vaccine and tell the patient to head on down to UCLA to have it made?

Of course not.

Does Adam mean that NWBO doesn’t have the manufacturing rights to the ATL-DC vaccine for which the trademarked name is DCVax-L?
Well, I doubt that. As it is obviously NWBO and not UCLA that will be filing for the manufacturing licenses with the regulators to manufacture the ATL-DC vaccine trademarked as DCVax-L.

And if the vaccine works in the combo trial, no matter what you call DCVax-L, that only helps Northwest, because the only place a patient will be able to get their vaccine manufactured will be from Northwest who will be (hopefully) licensed to sell it.

I hope this helps. — senti. :)